Literature DB >> 19347015

Endocrine and liver interaction: the role of endocrine pathways in NASH.

Paola Loria1, Lucia Carulli, Marco Bertolotti, Amedeo Lonardo.   

Abstract

This article reviews evidence that causally links hormonal disorders with hepatobiliary disease, and gives particular focus to nonalcoholic steatohepatitis (NASH). The downstream mechanisms by which endocrine disturbances cause liver disease might be similar to those involved in the development of primary liver disease. Hypothyroidism, for example, might lead to NASH, cirrhosis and potentially liver cancer via the development of hyperlipidemia and obesity. Patients with growth hormone deficiency have a metabolic-syndrome-like phenotype that is also associated with the development of NASH. Polycystic ovary syndrome is a common endocrine disorder that is often associated with insulin resistance, the metabolic syndrome, altered levels of liver enzymes and the development of NASH. Recent findings support a role of dehydroepiandrosterone sulfate deficiency in the development of advanced NASH. In addition, adrenal failure is increasingly reported in patients with end stage liver disease and in patients who have received a liver transplant, which suggests a bidirectional relationship between liver and endocrine functions. Clinicians should, therefore, be aware of the potential role of endocrine disorders in patients with cryptogenic liver disease and of the effects of liver function on the endocrine system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347015     DOI: 10.1038/nrgastro.2009.33

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  124 in total

1.  Mechanism of the development of obesity in animals with hypothalamic lesions.

Authors:  J R BROBECK
Journal:  Physiol Rev       Date:  1946-10       Impact factor: 37.312

2.  Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS.

Authors:  Mei-Jou Chen; Wei-Shiung Yang; Jehn-Hsiahn Yang; Chuhsing Kate Hsiao; Yu-Shih Yang; Hong-Nerng Ho
Journal:  Hum Reprod       Date:  2006-06-06       Impact factor: 6.918

3.  Hypothyroidism in patients with hepatocellular carcinoma treated by transarterial chemoembolization.

Authors:  Felix Flohr; Jan Harder; Jochen Seufert; Hubert E Blum; Hans C Spangenberg
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

4.  Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.

Authors:  Peer B Jacobson; Thomas W von Geldern; Lars Ohman; Marie Osterland; Jiahong Wang; Bradley Zinker; Denise Wilcox; Phong T Nguyen; Amanda Mika; Steven Fung; Thomas Fey; Annika Goos-Nilsson; Marlena Grynfarb; Tomas Barkhem; Kennan Marsh; David W A Beno; Bach Nga-Nguyen; Philip R Kym; James T Link; Noah Tu; Dale S Edgerton; Alan Cherrington; Suad Efendic; Benjamin C Lane; Terry J Opgenorth
Journal:  J Pharmacol Exp Ther       Date:  2005-03-22       Impact factor: 4.030

5.  The hepatoadrenal syndrome: a common yet unrecognized clinical condition.

Authors:  Paul E Marik; Timothy Gayowski; Thomas E Starzl
Journal:  Crit Care Med       Date:  2005-06       Impact factor: 7.598

6.  Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection.

Authors:  G Ghilardi; J J Gonvers; A So
Journal:  Br J Rheumatol       Date:  1998-12

7.  Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction.

Authors:  Leon A Adams; Ariel Feldstein; Keith D Lindor; Paul Angulo
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

8.  Induced hypothyroidism accelerates the regression of liver fibrosis in rats.

Authors:  Rafael Bruck; Sigal Weiss; Alexandra Traister; Isabel Zvibel; Hussein Aeed; Zamir Halpern; Ran Oren
Journal:  J Gastroenterol Hepatol       Date:  2007-12       Impact factor: 4.029

9.  Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.

Authors:  Fabián Arenas; Isabel Hervias; Miriam Uriz; Ruth Joplin; Jesús Prieto; Juan F Medina
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Intrahepatic cholestasis in subclinical and overt hyperthyroidism: two case reports.

Authors:  Aliye Soylu; Mustafa Gurkan Taskale; Aydin Ciltas; Mustafa Kalayci; A Baki Kumbasar
Journal:  J Med Case Rep       Date:  2008-04-21
View more
  53 in total

Review 1.  Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?

Authors:  Henry Völzke
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 2.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention.

Authors:  Valerio Nobili; Anna Alisi; Massimiliano Raponi
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

4.  Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

Authors:  Lucia Carulli; Stefano Ballestri; Amedeo Lonardo; Francesca Lami; Enrico Violi; Luisa Losi; Lisa Bonilauri; Anna Maria Verrone; Maria Rosaria Odoardi; Federica Scaglioni; Marco Bertolotti; Paola Loria
Journal:  Intern Emerg Med       Date:  2011-05-11       Impact factor: 3.397

Review 5.  Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?

Authors:  Giovanni Targher; Maurizio Rossini; Amedeo Lonardo
Journal:  Endocrine       Date:  2015-05-30       Impact factor: 3.633

Review 6.  Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment.

Authors:  Yue-Ye Huang; Aaron M Gusdon; Shen Qu
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

7.  Liver and diabetes. A vicious circle.

Authors:  Paola Loria; Amedeo Lonardo; Frank Anania
Journal:  Hepatol Res       Date:  2013-01       Impact factor: 4.288

8.  [Non-alcoholic steatohepatitis and cirrhosis in young adult patients with hypothalamic-pituitary dysfunction].

Authors:  D Goltz; K Schötta; H Zhou; H-P Fischer
Journal:  Pathologe       Date:  2013-07       Impact factor: 1.011

Review 9.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

10.  Chromosome 19 open reading frame 80 is upregulated by thyroid hormone and modulates autophagy and lipid metabolism.

Authors:  Yi-Hsin Tseng; Po-Yuan Ke; Chia-Jung Liao; Sheng-Ming Wu; Hsiang-Cheng Chi; Chung-Ying Tsai; Cheng-Yi Chen; Yang-Hsiang Lin; Kwang-Huei Lin
Journal:  Autophagy       Date:  2013-11-11       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.